Coagulopathy associated with COVID-19

Česká verze

Authors: Simona Bílková; Jana Hirmerová
Authors place of work: II. interní klinika LF UK a FN Plzeň
Published in the journal: Vnitř Lék 2020; 66(7): 402-408
Category: Přehledové články

Summary

Infection with a new type of coronavirus surprised with the diversity of its clinical symptoms. The disease may be asymptomatic, with only mild symptoms in the form of olfactory loss, general weakness or flu-like symptoms. However, in some patients, COVID-19 infection can be severe, with hypercoagulation being a common finding, with vascular endothelial damage and the consequent risk of venous and arterial thrombotic complications. Coa-gulopathy subsequently significantly worsens the prognosis of patients and increases overall mortality. Recently, a new term has been introduced to indicate the presence of activated hemostasis in SARS-CoV-2 infection - coagulopathy associated with COVID-19 (CAC). The current global pandemic of COVID-19 has triggered intensive research on the disease, which has clarified a number of findings about the infection, but we still have many unanswered questions, especially regarding possible treatment.

Keywords:

COVID-19 – D-dimers – heparine – immuno-trombosis – coagulopathy

Zdroje

1. Karetová D, Bultas J. Koagulopatie provázející těžší formy koronavirové infekce (COVID-19) - incidence trombotických komplikací, jak jim předcházet a jak je léčit. Cor Vasa.

2. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(6): 1421–1424.

3. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191: 145–147.

4. Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020; 191: 148–150.

5. Levolger S, Bokkers RPH, Wille J, Kropman RHJ, de Vries JPPM. Arterial thrombotic complications in COVID-19 patients [published online ahead of print, 2020 Jul 17]. J Vasc Surg Cases Innov Tech. 2020;doi:10.1016/j.jvscit.2020. 06. 012

6. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020; 382(17): e38.

7. Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19 [published online ahead of print, 2020 May 27]. J Thromb Haemost. 2020;10.1111/jth.14929. doi:10.1111/jth.14929

8. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4): 844–847.

9. Iba T, Levy JH, Warkentin TE, et al. Diagnosis and management of sepsis- induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019; 17(11): 1989–1994.

10. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 [published online ahead of print, 2020 May 21]. N Engl J Med. 2020;10.1056/NEJMoa2015432. doi:10.1056/NEJMoa2015432.

11. Liu Y, Sun W, Guo Y, et al. Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study. Platelets. 2020; 31(4): 490–496. doi :10.1080/09537104.2020.1754383.

12. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta- analysis. Clin Chim Acta. 2020; 506: 145–148. doi:10.1016/j.cca 2020. 03. 022

13. Zhang L, Yan X, Fan Q, et al. D- dimer levels on admission to predict in- hospital mortality in patients with Covid-19. J Thromb Haemost. 2020; 18(6): 1324–1329. doi:10.1111/ jth.14859.

14. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020; 18(5): 1023–1026.

15. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18(5): 1094–1099. doi:10.1111/jth.14817.

16. Thachil J. The versatile heparin in COVID-19. J Thromb Haemost.2020;18(5):1020-1022. doi:10.1111/jth.14821.

17. Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, Holley AB, Jimenez D, Le Gal G, Rali P, Wells P. Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. Chest. 2020 Sep; 158(3): 1143–1163. doi: 10.1016/j.chest.2020. 05. 559. Epub 2020 Jun 2. PMID: 32502594; PMCID: PMC7265858.

18. Marchandot B, Sattler L, Jesel L, et al. COVID-19 Related Coagulopathy: A Distinct.

19. Entity?. J Clin Med. 2020; 9(6): 1651. Published 2020 May 31. doi:10.3390/jcm9061651.

20. Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Confronting the controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome. Eur Respir J. 2020 Sep 3:2003006. doi: 10.1183/13993003.03006-2020. Epub ahead of print. PMID: 32883678; PMCID: PMC7474149.